Kaneka Corporation   Report issue

For profit Phase 1 Phase 2
Founded: Osaka Japan (1949)
Status: No NME R&D (1949)

Organization Overview

First Clinical Trial
2009
NCT00980694
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Kaneka Americas Holding Inc. | Kaneka Corporation | Kaneka Pharma America LLC | Kaneka Pharma Europe N.V.

Active Ingredients

Drugs in Phase 2 Trials (2)

multivitamins (1 trial)

ubiquinol (3 trials)

Drugs in Phase 1 Trials (1)

ubiquinone (1 trial)

Drugs in Other Trials (3)

chrysanthemum flower oil (1 trial)

lactobacillus plantarum (1 trial)

Pediococcus acidilactici (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 1)

Heart Arrest (Phase 2)

Huntington Disease (Phase 1)

Sepsis (Phase 2)

Toxemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6